Dynavax to Present Data on SD-101 in Combination with KEYTRUDA(R) at the 2017 American Society of Clinical Oncology (ASCO) Annual ...
BERKELEY, CA--(Marketwired - May 19, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that updated data from an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® ( …